Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.
COVID-19
antivirals
immunosuppression
lymphoma
myeloma
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
25 Dec 2023
25 Dec 2023
Historique:
received:
24
05
2022
accepted:
19
11
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
26
12
2023
Statut:
aheadofprint
Résumé
Despite widespread vaccination rates, we are living with high transmission rates of SARS-CoV-2. Although overall hospitalisation rates are falling, the risk of serious infection remains high for patients who are immunocompromised because of haematological malignancies. In light of the ongoing pandemic and the development of multiple agents for treatment, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 management in patients with haematological disorders. It is our recommendation that both patients with haematological malignancies and treating specialists be educated regarding the preventive and treatment options available and that patients continue to receive adequate vaccinations, keeping in mind the suboptimal vaccine responses that occur in haematology patients, in particular, those with B-cell malignancies and on B-cell-targeting or depleting therapy. Patients with haematological malignancies should receive treatment for COVID-19 in accordance with the severity of their symptoms, but even mild infections should prompt early treatment with antiviral agents. The issue of de-isolation following COVID-19 infection and optimal time to treatment for haematological malignancies is discussed but remains an area with evolving data. This position statement is to be used in conjunction with advice from infectious disease, respiratory and intensive care specialists, and current guidelines from the National COVID-19 Clinical Evidence Taskforce and the New Zealand Ministry of Health and Cancer Agency Te Aho o Te Kahu COVID-19 Guidelines.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 2020; 136: 2881-2892.
McCaughan G, Di Ciaccio P, Ananda-Rajah M, Gilroy N, MacIntyre R, Teh B et al. COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Intern Med J 2021; 51: 763-768.
Gong I, Vijenthira A, Betschel S, Hicks LK, Cheung M. COVID-19 vaccine response in patients with hematologic malignancy: a systematic review and meta-analysis. Blood 2021; 138: 4113.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-1931.
Shen Y, Freeman JA, Holland J, Solterbeck A, Naidu K, Soosapilla A et al. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity. Br J Haematol 2022; 197: 41-51.
Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020; 383: 2439-2450.
Shen Y, Freeman JA, Holland J, Naidu K, Solterbeck A, Van Bilsen N et al. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. Blood 2022; 140: 2709-2721.
Ng KYY, Zhou S, Tan SH, Ishak NDB, Goh ZZS, Chua ZY et al. Understanding the psychological impact of COVID-19 pandemic on patients with cancer, their caregivers, and health care workers in Singapore. JCO Glob Oncol 2020; 6: 1494-1509.
Hamad N, Ananda-Rajah M, Gilroy N, MacIntyre R, Gottlieb D, Ritchie D et al. Australia and New Zealand transplant and cellular therapies COVID-19 vaccination consensus position statement. Intern Med J 2021; 51: 1321-1323.
Perram J, Purtill D, Bajel A, Butler J, O'Brien T, The B et al. ANZTCT position statement: COVID-19 management in haematopoietic stem cell transplant and chimeric antigen receptor T cell patients. Intern Med J 2022; 53: 119-125.
Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J 2020; 50: 667-679.
Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv 2022; 6: 2014-2034.
Beaton B, Sasson SC, Rankin K, Raedemaeker J, Wong A, Hastak P et al. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses. Am J Hematol 2023; 98: 131-139.
Alcheikh A, Perkins GB, Pucar PA, Cecchin A, Chai CS, Tunbridge M et al. Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients. Blood. Cancer J 2023; 13: 50.
Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood 2022; 139: 678-685.
Shen Y, Freeman J, Kerridge I, Naidu K, Holland J, Mulligan S. PB1934: measured optimum anti-spike level vaccination strategy and anti-viral access result in low covid hospitalisation and mortality in CLL and MBL. Hemasphere 2023; 7: e83221a1.
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J 2021; 11: 138.
Van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell 2021; 39: 1028-1030.
Maneikis K, Sablauskas K, Ringeleviciute U, Vaitekenaite V, Cekauskiene R, Kryzauskaite L et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol 2021; 8: e583-e592.
Guglielmelli P, Mazzoni A, Maggi L, Kiros ST, Zammarchi L, Pilerci S et al. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol 2021; 96: E408-E410.
Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol 2021; 14: 81.
Marasco V, Carniti C, Guidetti A, Farina L, Magni M, Miceli R et al. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol 2022; 196: 548-558.
Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021; 27: 1652-1657.
Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. medRxiv 2021: 2021.07.08.21259776.
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Seegobin S et al. LB5. PROVENT: phase 3 study of efficacy and safety of AZD7442 (tixagevimab/cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults. Open Forum Infect Dis 2021; 8: S810.
Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19. JAMA 2022; 327: 384-385.
Touret F, Baronti C, Pastorino B, Villarroel PMS, Ninove L, Nougairede A et al. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5. Sci Rep 2022; 12: 12609.
Aggarwal A, Akerman A, Milogiannakis V, Silva MR, Walker G, Stella AO et al. SARS-CoV-2 Omicron BA.5: evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. EBioMedicine 2022; 84: 104270.
Health NZMo. Cancer Care and COVID-19. Available from URL: https://teaho.govt.nz/covid-19/covid19
Taskforce NC-CE. Caring for People With COVID-19. Available from URL: https://covid19evidence.net.au/#living-guidelines
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 2021; 385: 1941-1950.
Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 2023; 401: 281-293.
Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020; 383: 2291-2293.
Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech AM, Lane C et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis 2020; 222: 1103-1107.
Khatamzas E, Rehn A, Muenchhoff M, Hellmuth J, Gaitzsch E, Weiglein T et al. Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host. medRxiv 2021: 2021.01.10.20248871.
Ending Isolation: Centers for Disease Control and Prevention; 2022. Available from URL: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html
Guidance on Ending the Isolation Period for People with COVID-19, Third Update: European Centre for Disease Prevention and Control; 2022 [Cited 2022 Nov 22. Available from URL: https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolation
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133-146.